Maki Oncology Clinic: Low-Dose Immunotherapy Protocols
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Maki Oncology Clinic (Nagoya) is one of our partner clinics. Since 2015, the clinic has used a lower dose of the prescription anti-PD-1 antibody nivolumab (brand name Opdivo) than the approved dose, as its own protocol.
Immune Protocols at the Clinic
- Low-dose Opdivo (nivolumab) and Yervoy (ipilimumab): According to the clinic, doses as low as 20 mg of Opdivo are used. This is the clinic's own protocol rather than an approved regimen, and side effects can still occur.
- Combination with cell therapy: Drug therapy is combined with cultured NK cells.
- Published data: The clinic cites data from international clinical studies. Please ask the clinic for details, and discuss with your physician whether this approach is suitable for you.
[Medical Supporter Compliance Statement] Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.